UNASSIGNED:使用年龄相关性黄斑变性(AMD)患者的脂蛋白颗粒组成和大小以及载脂蛋白指标的核磁共振定量测量,研究血清胆固醇流出能力(血清接受胆固醇的能力)及其调节因素。
未经评估:病例对照研究。
未经评估:80例早期AMD(eAMD)患者的四百二份血清样本,和212名新生血管性AMD(nAMD)患者,包括80例典型nAMD(tAMD)和132例息肉状脉络膜血管病变(PCV),和110名年龄和性别匹配的对照参与者。
UNASSIGNED:参与者的血清显示使用体外细胞测定法测量的胆固醇流出能力和使用核磁共振测量的脂蛋白亚组分(南丁格尔,有限公司)。在患者和对照参与者中研究了胆固醇流出能力(以百分比衡量)与脂质亚组分之间的关联。
未经证实:对照组的胆固醇外排能力和脂质亚组分,eAMD,和nAMD。HDL亚组分与胆固醇流出能力之间的关联。
UNASSIGNED:调整年龄后,eAMD患者(68.0±11.3%[平均值±标准偏差])和nAMD患者(75.9±27.7%)的胆固醇外排能力高于对照组(56.9±16.7%),性别,并使用降脂药(P<0.0001)。核磁共振脂质组学显示,eAMD(9.96±0.27mm[平均值±标准偏差])和PCV(9.97±0.23mm)的HDL平均直径均大于对照组(9.84±0.24mm;两者P=0.0001)。在28个HDL亚组分中,大部分的小,中等,和大型HDLs,但是7个超大的HDLs没有一个,与eAMD和PCV的胆固醇流出能力中度相关(R=0.149-0.277)。
未经证实:eAMD和PCV的血清胆固醇流出能力增加,但不是tAMD,可能反映了tAMD和PCV中脂质失调的潜在病理生理学特征的差异。进一步的研究应针对研究HDL在AMD中的多种生物学活性,包括黄斑色素运输,炎症的调节,和局部胆固醇运输系统。
UNASSIGNED: To investigate serum cholesterol efflux capacity (the ability of the serum to accept cholesterol) and factors that regulate it using nuclear magnetic resonance-quantified measures of lipoprotein particle composition and size and apolipoproteins metrics in patients with age-related macular degeneration (AMD).
UNASSIGNED: Case-control study.
UNASSIGNED: Four hundred two serum samples from 80 patients with early AMD (eAMD), and 212 patients with neovascular AMD (nAMD), including 80 with typical nAMD (tAMD) and 132 with polypoidal choroidal vasculopathy (PCV), and 110 age- and gender matched control participants.
UNASSIGNED: Serum from participants showed cholesterol efflux capacity measured using in vitro cell assays and lipoprotein subfractions measured using nuclear magnetic resonance (Nightingale, Ltd). Associations between cholesterol efflux capacity (measured in percentage) and lipid subfractions were investigated in the patients and control participants.
UNASSIGNED: Cholesterol efflux capacity and lipid subfractions in control, eAMD, and nAMD. Associations between HDL subfractions and cholesterol efflux capacity.
UNASSIGNED: Cholesterol efflux capacity was higher in patients with eAMD (68.0 ± 11.3% [mean ± standard deviation]) and nAMD (75.9 ± 27.7%) than in the control participants (56.9 ± 16.7%) after adjusting for age, gender, and use of lipid-lowering drug (P < 0.0001). Nuclear magnetic resonance lipidomics demonstrated that the mean diameter of HDL was larger both in eAMD (9.96 ± 0.27 mm [mean ± standard deviation]) and PCV (9.97 ± 0.23 mm) compared with that of the control participants (9.84 ± 0.24 mm; P = 0.0001 for both). Among the 28 HDL subfractions, most of the small, medium, and large HDLs, but none of the 7 extra large HDLs fractions, were associated moderately with cholesterol efflux capacity in eAMD and PCV (R = 0.149-0.277).
UNASSIGNED: Serum cholesterol efflux capacity was increased in eAMD and PCV, but not tAMD, possibly reflecting differential underlying pathophysiologic features of lipid dysregulation in tAMD and PCV. Further studies should be directed toward investigating the diverse biological activities of HDL in AMD, including macular pigment transport, regulation of inflammation, and local cholesterol transport system.